<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1337">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089476</url>
  </required_header>
  <id_info>
    <org_study_id>3083</org_study_id>
    <nct_id>NCT03089476</nct_id>
  </id_info>
  <brief_title>Early Intervention With Lipid-Rich Barrier Cream in Infants at High Risk of Atopy</brief_title>
  <official_title>Hypothesis: Early Intervention With Lipid-Rich Barrier Cream Improves Skin Barrier Function in Infants at High Risk of Atopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PuraCap Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that food allergy is preceded by atopic dermatitis (AD), due to a
      disruption of skin barrier which can predispose one to food sensitization through the skin.
      Lipid-enriched moisturizers are widely used in AD as ongoing treatment and maintenance skin
      care. The investigators hypothesize that early intervention with lipid-rich barrier cream in
      infants at high risk of atopy will prevent skin barrier dysfunction, and thereby prevent the
      risk of epicutaneous food allergen sensitization.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Children at high risk of atopy will be randomly assigned to skin care with daily, whole body application of EpiCeram® vs. standard of care. Parents of infants assigned to current standard of care for infant skin will use petrolatum jelly to be applied as needed for dry skin. Additionally, children randomized to the treatment group (EpiCeram®) will also be permitted to use petrolatum jelly as needed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Outcomes Assessor</masking>
    <masking_description>The clinician performing both SCORAD assessments and skin prick testing will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Skin prick testing to milk, egg, and peanut</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Food Allergen Sensitization measured by positive skin prick testing to milk, egg, and peanut measured as positive or negative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scoring Atopic Dermatitis (SCORAD) values</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Prevalence of Atopic Dermatitis measured by SCORAD values ranging from 0 (none) to 83 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial Transepidermal Water Loss (TEWL)</measure>
    <time_frame>12 months</time_frame>
    <description>Skin Barrier Assessment measured through serial transepidermal water loss (TEWL) in grams of water/meters-squared/hour</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Eczema</condition>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>Treatment Skin Care Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parents of infants assigned to treatment skin care group for infant skin will use EpiCeram® on whole body once daily. These subjects will also be permitted to use petrolatum jelly as needed. The frequency of infant bathing will be left up to the parents based on lack of evidence-based recommendations regarding bathing. If an infant on treatment with EpiCeram® receives a bath, the daily EpiCeram application will occur after the bath and gentle drying of the skin. All subjects will be asked to avoid any topical emollient (petrolatum or EpiCeram®) 12 hours prior to their clinic visits to prevent potential interference with TEWL and/or STS testing and results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Skin Care Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Parents of infants assigned to current standard of care for infant skin will use petrolatum jelly to be applied as needed for dry skin. The frequency of infant bathing will be left up to the parents based on lack of evidence-based recommendations regarding bathing. All subjects will be asked to avoid any topical emollient (petrolatum or EpiCeram®) 12 hours prior to their clinic visits to prevent potential interference with TEWL and/or STS testing and results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EpiCeram</intervention_name>
    <description>Daily administration</description>
    <arm_group_label>Treatment Skin Care Group</arm_group_label>
    <other_name>skin barrier emulsion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Petrolatum ointment</intervention_name>
    <description>Daily administration</description>
    <arm_group_label>Control Skin Care Group</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with physician confirmed pregnancy at a gestational age of ≥ 34 weeks. Infants
             at high risk for atopy will have one or both parents affected by an allergic disease.
             Infants at low risk for atopy will have no parent or sibling affected by allergic
             disease.

        Exclusion Criteria:

          -  Pregnancy loss or delivery prior to a gestational age of ≥ 34 weeks, a history of
             substance or alcohol abuse, psychiatric and developmental co-morbidities that would
             render a subject unable to provide informed consent or perform study-related
             procedures, AIDS and HIV infection, or a fetus with chromosomal or congenital
             abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>34 Weeks</minimum_age>
    <maximum_age>42 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pia Hauk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Robinson, DO</last_name>
    <phone>720-394-1189</phone>
    <email>RobinsonM2@NJHealth.org</email>
  </overall_contact>
  <reference>
    <citation>Walker L, Downe S, Gomez L. Skin care in the well term newborn: two systematic reviews. Birth. 2005 Sep;32(3):224-8. Review.</citation>
    <PMID>16128978</PMID>
  </reference>
  <reference>
    <citation>Blume-Peytavi U, Hauser M, Stamatas GN, Pathirana D, Garcia Bartels N. Skin care practices for newborns and infants: review of the clinical evidence for best practices. Pediatr Dermatol. 2012 Jan-Feb;29(1):1-14. doi: 10.1111/j.1525-1470.2011.01594.x. Epub 2011 Oct 20. Review.</citation>
    <PMID>22011065</PMID>
  </reference>
  <reference>
    <citation>Elias PM. Lipid abnormalities and lipid-based repair strategies in atopic dermatitis. Biochim Biophys Acta. 2014 Mar;1841(3):323-30. doi: 10.1016/j.bbalip.2013.10.001. Epub 2013 Oct 12. Review.</citation>
    <PMID>24128970</PMID>
  </reference>
  <reference>
    <citation>Mao-Qiang M, Brown BE, Wu-Pong S, Feingold KR, Elias PM. Exogenous nonphysiologic vs physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol. 1995 Jul;131(7):809-16.</citation>
    <PMID>7611797</PMID>
  </reference>
  <reference>
    <citation>Feingold KR, Elias PM. Role of lipids in the formation and maintenance of the cutaneous permeability barrier. Biochim Biophys Acta. 2014 Mar;1841(3):280-94. doi: 10.1016/j.bbalip.2013.11.007. Epub 2013 Nov 18. Review.</citation>
    <PMID>24262790</PMID>
  </reference>
  <reference>
    <citation>Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, Brown SJ, Chen Z, Chen Y, Williams HC. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014 Oct;134(4):818-23. doi: 10.1016/j.jaci.2014.08.005.</citation>
    <PMID>25282563</PMID>
  </reference>
  <reference>
    <citation>Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, Shigematsu Y, Yoshida K, Niizeki H, Motomura K, Sago H, Takimoto T, Inoue E, Kamemura N, Kido H, Hisatsune J, Sugai M, Murota H, Katayama I, Sasaki T, Amagai M, Morita H, Matsuda A, Matsumoto K, Saito H, Ohya Y. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014 Oct;134(4):824-830.e6. doi: 10.1016/j.jaci.2014.07.060.</citation>
    <PMID>25282564</PMID>
  </reference>
  <reference>
    <citation>Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD; NISC Comparative Sequence Program., Murray PR, Turner ML, Segre JA. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012 May;22(5):850-9. doi: 10.1101/gr.131029.111. Epub 2012 Feb 6.</citation>
    <PMID>22310478</PMID>
  </reference>
  <reference>
    <citation>Kircik LH, Del Rosso JQ. Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids. J Clin Aesthet Dermatol. 2011 Dec;4(12):25-31.</citation>
    <PMID>22191005</PMID>
  </reference>
  <reference>
    <citation>Kelleher MM, Dunn-Galvin A, Gray C, Murray DM, Kiely M, Kenny L, McLean WH, Irvine AD, Hourihane JO. Skin barrier impairment at birth predicts food allergy at 2 years of age. J Allergy Clin Immunol. 2016 Apr;137(4):1111-6.e1-8. doi: 10.1016/j.jaci.2015.12.1312.</citation>
    <PMID>26924469</PMID>
  </reference>
  <reference>
    <citation>Peters RL, Allen KJ, Dharmage SC, Tang ML, Koplin JJ, Ponsonby AL, Lowe AJ, Hill D, Gurrin LC; HealthNuts Study.. Skin prick test responses and allergen-specific IgE levels as predictors of peanut, egg, and sesame allergy in infants. J Allergy Clin Immunol. 2013 Oct;132(4):874-80. doi: 10.1016/j.jaci.2013.05.038. Epub 2013 Jul 24.</citation>
    <PMID>23891354</PMID>
  </reference>
  <reference>
    <citation>Halken S. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol. 2004 Jun;15 Suppl 16:4-5, 9-32. Review.</citation>
    <PMID>15125698</PMID>
  </reference>
  <reference>
    <citation>Minasyan A, Babajanyan A, Campbell DE, Nanan R. Validation of a Comprehensive Early Childhood Allergy Questionnaire. Pediatr Allergy Immunol. 2015 Sep;26(6):522-9. doi: 10.1111/pai.12415. Epub 2015 Jul 22.</citation>
    <PMID>26031325</PMID>
  </reference>
  <reference>
    <citation>Kelleher MM, O'Carroll M, Gallagher A, Murray DM, Dunn Galvin A, Irvine AD, Hourihane JO. Newborn transepidermal water loss values: a reference dataset. Pediatr Dermatol. 2013 Nov-Dec;30(6):712-6. doi: 10.1111/pde.12106. Epub 2013 Mar 5.</citation>
    <PMID>23458265</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 23, 2017</lastchanged_date>
  <firstreceived_date>March 20, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Melissa Robinson</investigator_full_name>
    <investigator_title>Allergy Fellow</investigator_title>
  </responsible_party>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Decanoic acid</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
